|Bid||65.00 x 1200|
|Ask||70.98 x 1000|
|Day's Range||70.54 - 71.38|
|52 Week Range||50.77 - 92.18|
|Beta (3Y Monthly)||1.24|
|PE Ratio (TTM)||54.76|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CFO of Genomic Health Inc (30-Year Financial, Insider Trades) G Bradley Cole (insider trades) sold 43,112 shares of GHDX on 09/10/2019 at an average price of $72.22 a share. Continue reading...
Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Seeking to win where no one has succeeded before in cancer and build out its own manufacturing, this Mountain View company takes its place in a growing line of Bay Area biotech IPOs.
Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
President and CEO of Genomic Health Inc (30-Year Financial, Insider Trades) Kimberly J Popovits (insider trades) sold 50,000 shares of GHDX on 08/09/2019 at an average price of $73.76 a share. Continue reading...
The merger of Genomic Health (GHDX) with Exact Sciences will combine two of the strongest brands in cancer diagnostics, Cologuard and OncotypeDX, providing platform for growth.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 1) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Odonate ...
Kim Popovits helped build Genomic Health into a leading molecular diagnostics company over a 17-year career. She could leave the Redwood City company with millions of dollars.
Pfizer announced an all-stock plan Monday to combine its off-patent and generic drugs unit, Upjohn, with generic drug maker Mylan. That sent Mylan stock flying as Pfizer stumbled.
The $2.8 billion acquisition deal will equip Madison's Exact Sciences with infrastructure to deliver a new blood-based test it's been developing with Mayo Clinic to accurately detect liver cancer.
Exact Sciences reported better-than-expected second quarter financial results, but a merger agreement with Genomic Health sent shares lower.
Shares are heading in opposite directions after the two cancer diagnostic companies surprised Wall Street by revealing plans to merge. Here's what investors need to know.
The combined company is expected to generate revenue of approximately $1.6 billion in 2020 and have a commercial presence in more than 90 countries
A new ETF is setting its sights on advancing the field of health care technology. ROBO Global Healthcare Technology and Innovation ETF is giving investors another option to capture innovation and growth within the space. Travis Briggs, ROBO Global CEO, discusses with Yahoo Finance's Akiko Fujita on "The Ticker."